Recruiting PHASE4 INTERVENTIONAL 2-arm
NCT07404436
Rivaroxaban in Idiopathic Membranous Nephropathy
Efficacy of Rivaroxaban for Thromboprophylaxis in Idiopathic Membranous Nephropathy: A Prospective, Single-Center, Randomized Controlled Trial
Sponsor: Beijing Friendship Hospital
Conditions
Idiopathic Membranous Nephropathy
Interventions
Rivaroxaban 10 MG Warfarin Sodium
Updated 1 time since 2026 Last updated: Feb 5, 2026 Started: Jan 5, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE4 clinical study on Idiopathic Membranous Nephropathy, this trial is actively recruiting participants. The trial is conducted by Beijing Friendship Hospital and has accumulated 1 data snapshot since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Recruiting — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Beijing Friendship Hospital
Data source: Beijing Friendship Hospital
For direct contact, visit the study record on ClinicalTrials.gov .